Results 111 to 120 of about 76,298 (277)

Azathioprine for multiple sclerosis.

, 2007
BACKGROUND: Azathioprine is the most widely used immunosuppressive treatment in multiple sclerosis (MS). It is an alternative to interferon beta for treating MS also because it is less expensive. Concerns about its safety, mainly a possible increased
Iuliano G, Filippini G., CASETTA, Ilaria
core  

Applying Machine Learning Models to Predict Medication Nonadherence in Crohn’s Disease Maintenance Therapy

Patient Preference and Adherence, 2020
Lei Wang,1,* Rong Fan,1,* Chen Zhang,1 Liwen Hong,1 Tianyu Zhang,1 Ying Chen,2 Kai Liu,2 Zhengting Wang,1 Jie Zhong1 1Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of ...
Wang L, Fan R, Zhang C, Hong L, Zhang T, Chen Y, Liu K, Wang Z, Zhong J   +8 more
doaj  

Old disease, new twist

Journal of Hospital Medicine, EarlyView.
Abstract An 81‐year‐old man with a history of high‐grade urothelial carcinoma of the bladder and ureter on treatment with atezolizumab and tiragolumab presented to the emergency department with 5 months of malaise, generalized weakness, and fatigue and 2 weeks of subjective fevers. One month prior to presentation, he received an empiric 9‐day course of
Hadi Roudsari, Gurpreet Dhaliwal, Anand D. Jagannath, Alan H. Baik, Sam Brondfield   +4 more
wiley   +1 more source

Growth and development in paediatric onset inflammatory bowel disease: Data analysis from the CEDATA registry

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objective Different therapies may affect the growth and development of children and adolescents with inflammatory bowel disease (IBD) supporting specific therapy algorithms for paediatric Crohn's disease (CD) and ulcerative colitis (UC). Methods Growth and development data from the German–Austrian CEDATA‐GPGE registry entered between 2004 and ...
Ilse Broekaert, Anna Schmidt, Christoph Hünseler, Jan Delaffolie, CEDATA Study Group   +4 more
wiley   +1 more source

Exacerbation of hereditary warfarin resistance by azathioprine

, 2011
A 39-year-old Afro-Caribbean man with Crohn disease with recurrent deep vein thromboses and pulmonary emboli was commenced on lifelong warfarin treatment.
Campbell, Simon, Pushpakom, Sudeep P., Gambhir, Nikki, Latif, Ayshe; id_orcid, Hadfield, Kristen D., Newman, William G.; id_orcid   +5 more
core   +1 more source

Association of attention‐deficit/hyperactivity disorder and autism with inflammatory bowel disease activity

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives To estimate the effect of attention deficit hyperactivity disorder (ADHD) and autism on the disease activity of inflammatory bowel disease (IBD) in pediatric and young patients. Methods Patients diagnosed with IBD between the ages of 6 and 24 years were identified in Danish nationwide registries 1996–2022.
Sabine Jansson, Mads Damsgaard Wewer, Johan Burisch, Matthew P. Fox, Michael E. Benros, Charlotte Ulrikka Rask, Vibeke Wewer, Mikkel Malham   +7 more
wiley   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience

JPGN Reports, EarlyView.
Abstract Objectives To evaluate the durability and predictors of loss of response of infliximab (IFX) over 2 years in paediatric Crohn's disease (CD) utilizing a proactive therapeutic drug monitoring (TDM) strategy. Methods A retrospective, single‐centre cohort study was conducted at The Children's Hospital at Westmead (CHW), Australia, from January ...
Cher Wei Chuah, Jessica Eldredge, Annabel Magoffin, Edward Vincent O'Loughlin, Calvin Joomann Park, Juliana Puppi, Susan Siew, Michael Stormon, Kunal Thacker, Shoma Dutt   +9 more
wiley   +1 more source

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Daniel Himelstein, Megan McNicol, Mahmoud Abdel‐Rasoul, Brendan M. Boyle, Hilary K. Michel, Ross Maltz   +5 more
wiley   +1 more source

A joint transdisciplinary approach for paediatric inflammatory bowel disease: Integrating nursing, dietetic and psychological support

JPGN Reports, EarlyView.
Abstract Paediatric inflammatory bowel disease (pIBD) is a long‐term, immune‐mediated condition characterised by fluctuating gastrointestinal symptoms, nutritional risk and psychosocial difficulties. Although multidisciplinary team (MDT) support is considered the gold standard, there is considerable variation in how it is delivered, and it remains ...
King‐Chi Yau, Laura Tesser, Kay Crook
wiley   +1 more source